Persevere Therapeutics, Inc. is a Delaware-incorporated, clinical-stage oncology company based in Chesterbrook, Pennsylvania, developing misetionamide as a first-in-class cancer therapeutic.
Subscribe to see Persevere Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Persevere Therapeutics Inc. is a company headquartered in Chesterbrook, United States. Its most recent funding round, Seed, raised $1.6M in February 2026. Xcout tracks 10 named people at Persevere Therapeutics Inc., including Greg Bosch (CEO).
As of 16 November 2026. Source: Xcout Intel.
4 more named people on record for Persevere Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1.6M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Persevere Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Perthera, Inc. is a therapeutic intelligence company headquartered in Burlington, North Carolina, that advances precision oncology and personalized medicine through its proprietary testing and analysis platform.
Avstera Therapeutics, Inc. is an oncology-focused biopharmaceutical holding company located in Malvern, Pennsylvania, engaged in drug pipelines and therapeutic development.
Resolute Science, Inc. is a pre-clinical life science company aiming to develop a safe, effective, and novel therapeutic for the treatment of solid tumors.
PIC Therapeutics, Inc. is a biopharmaceutical company headquartered in Natick, Massachusetts, dedicated to developing life-changing medicines for patients with cancer. The company focuses on oncology research and therapeutic product development.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Persevere Therapeutics Inc.? Suggest a correction · Work at Persevere Therapeutics Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.